H7N9 Bird Flu Virus - Biotech, Pharma and Life Science Channel

13:10 EDT 3rd August 2015 | BioPortfolio

Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally been found to infect humans, no human infections with H7N9 viruses have been reported until recent reports from China.

News Articles [6 Associated News Articles listed on BioPortfolio]

Investigation of Ansun Biopharma Dismissed, Company Continues Development of Therapies for Severe Respiratory Infections

SAN DIEGO, July 27, 2015 /PRNewswire/ -- Ansun BioPharma, Inc., a San Diego-based biotech company, is pleased to announce that an investigation by the United States Attorney's office over the miscondu...

Ansun BioPharma Publishes Effects of FluDase™ on Drug Resistant Flu

SAN DIEGO, July 7, 2015 /PRNewswire/ -- Ansun Biopharma announced today the publication of the report "Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibro...

Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza

Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectiou...

Medicago to build $245M production facility in Quebec City

New complex will make vaccines and therapeutics using innovative plant technology QUEBEC CITY, May 19, 2015 /PRNewswire/ - Medicago, a major Canadian biotech company and an international leader in ...

Pandemic Influenza - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, Pandemic Influenza - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-01-29. This 135-page report is available in...

Medicago awarded a contract by the U.S. Department of Health and Human Services to explore alternate production methods for Ebola antibodies

QUEBEC CITY, Feb. 24, 2015 /PRNewswire/ - Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Clinical Trials [8 Associated Clinical Trials listed on BioPortfolio]

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine ...

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

This is a Phase II randomized, partially-blinded, controlled trial in 360 (up to 600) males and females, 65 years of age and older, who are in good health and meet all eligibility criteria...

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Background:< TAB> - Flu virus that causes disease in birds can sometimes spread to people. It can cause severe illness, even death. Vaccines are used to try to create resistance to such i...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility crit...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

A phase I prospective, randomized study in healthy adult subjects at a single center. Adult subjects age 18 to 47 years and meeting all enrollment criteria will choose to participate as s...

PubMed Articles [39 Associated PubMed Articles listed on BioPortfolio]

Extra-pulmonary viral shedding in H7N9 Avian Influenza patients.

The clinical features of avian-origin influenza virus A (H7N9) virus infection have been extensively characterized, but viral RNA detection in extra-pulmonary samples has seldom been studied.

Diagnostics-in-a-Suitcase: Development of a portable and rapid assay for the detection of the emerging avian influenza A (H7N9) virus.

In developing countries, equipment necessary for diagnosis is only available in few central laboratories, which are less accessible and of limited capacity to test large numbers of incoming samples. M...

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor immunogen necessitating evaluation of ...

Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.

A novel avian-origin influenza A H7N9 virus emerged in China in 2013 and continues to cause sporadic human infections with mortality rates approaching 35%. Currently there are no approved human vaccin...

Surveillance of Influenza A Virus and Its Subtypes in Migratory Wild Birds of Nepal.

Nepal boarders India and China and all three countries lie within the Central Asian Flyway for migratory birds. Novel influenza A H7N9 caused human fatalities in China in 2013. Subclinical infections ...

H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.

Avian-origin H7N9 influenza is a novel influenza A virus (IAV) that emerged in humans in China in 2013. Using immunoinformatics tools, we identified several H7N9 T cell epitopes with T cell receptor (...

ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.

In a previously reported phase I clinical trial, subjects vaccinated with two doses of an unadjuvanted H7N9 virus like particle (VLP) vaccine responded poorly (15.6% seroconversion rates with 45μg he...

Host genes and influenza pathogenesis in humans: an emerging paradigm.

The emergence of the pandemic influenza virus A(H1N1)pdm09 in 2009 and avian influenza virus A(H7N9) in 2013 provided unique opportunities for assessing genetic predispositions to severe disease becau...

Amino Acid Substitutions Improve the Immunogenicity of H7N7HA Protein and Protect Mice against Lethal H7N7 Viral Challenge.

Avian influenza A H7N7/NL/219/03 virus creates a serious pandemic threat to human health because it can transmit directly from domestic poultry to humans and from human to human. Our previous vaccine ...

Human infection with an avian influenza A (H9N2) virus in the middle region of China.

During the epidemic period of the novel H7N9 viruses, an influenza A (H9N2) virus was isolated from a 7-year-old boy with influenza-like illness in Yongzhou city of Hunan province in November 2013. To...

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.


Advertisement
 

Relevant Topics

Influenza
Latest News Clinical Trials Research Drugs Reports Corporate
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Public Health
Latest News Clinical Trials Research Drugs Reports Corporate
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Swine Flu - H1N1 influenza - H7N9
Latest News Clinical Trials Research Drugs Reports Corporate
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

Advertisement
 
review and buy H7N9 Bird Flu Virus market research data and corporate reports here

Channels Quicklinks